Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand;
Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Thailand.
Anticancer Res. 2021 Dec;41(12):5913-5918. doi: 10.21873/anticanres.15410.
The safety windows and toxicity of clinically available known drugs allow drug repurposing to be a popular treatment strategy for several diseases, including cancers. Several common drugs, e.g., metformin, statin, and aspirin are on clinical trials for repurposing in oncology treatment. Most of repurposed drugs, however, cannot be used as single agents and some do not exert any clinically significant effects. The limitations and possible biases from observational studies and preclinical models to repurpose these drugs are debatable. In this article, the limitations and probability of using metformin, one of the most repurposed drugs for cancer treatment and in oncological practice, are discussed.
临床可用的已知药物的安全性窗口和毒性使得药物重定位成为多种疾病(包括癌症)的一种流行治疗策略。几种常用药物,如二甲双胍、他汀类药物和阿司匹林,正在进行癌症治疗的重新定位临床试验。然而,大多数重新定位的药物不能单独使用,有些药物没有产生任何临床显著效果。从观察性研究和临床前模型重新定位这些药物的局限性和可能存在的偏见是有争议的。在本文中,讨论了最常用于癌症治疗和肿瘤学实践的药物之一——二甲双胍的局限性和使用可能性。